1. Inicio
  2. Publicaciones
  3. Long-term docosahexaenoic acid (DHA) supplementation in cystic fibrosis patients: a randomized, multi-center, double-blind, placebo-controlled trial.

Long-term docosahexaenoic acid (DHA) supplementation in cystic fibrosis patients: a randomized, multi-center, double-blind, placebo-controlled trial.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • López-Neyra A
  • Suárez L
  • Muñoz M
  • de Blas A
  • Ruiz de Valbuena M
  • Garriga M
  • Girón Moreno R
  • Máiz L
  • González D
  • Bousoño C
  • Manzanares J
  • Pastor Ó
  • Martínez-Botas J
  • Del Campo R
  • Cantón R
  • Roy G
  • Menacho M
  • Arroyo D
  • Zamora J
  • Soriano JB
  • Lamas A

Grupos

Abstract

Cystic fibrosis (CF) patients have an alteration in fatty acid (FA) metabolism, associated with increased omega-6 and low omega-3 FA. Previous studies on supplementation with omega-3 FA in CF had contradictory results, and to date there is no evidence to recommend routine use of omega-3 supplements in CF patients. We hypothesized that long-term supplementation with docosahexaenoic acid (DHA) will have beneficial effects in these patients, by reducing pulmonary, systemic and intestinal inflammation.

Datos de la publicación

ISSN/ISSNe:
0952-3278, 1532-2823

PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS  Churchill Livingstone

Tipo:
Article
Páginas:
102186-102186
PubMed:
33038833
Factor de Impacto:
1,059 SCImago ℠
Cuartil:
Q2 SCImago ℠

Citas Recibidas en Web of Science: 14

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Cystic Fibrosis, Docosahexaenoic acid, Essential fatty acids, Inflammation, Interleukin-8, Omega-3 Fatty Acids

Cita

Compartir